UNSPSC 51282129: Faropenem medoxomil

This classification denotes a beta-lactam antibiotic C17H19NO8S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5OK523O4FU, chemically known as (5-methyl-2-oxo-1,3-dioxoren-4-yl)methyl(5r,6s)-6-((r)-1-hydroxyethyl)-7-oxo-3-((r)-2-tetrahydrofuryl)-4-thia-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylate, but more generally known as faropenem medoxomil, which bears US NIH Compound Identifier 6918218. Most nations, for tariff and trade purposes, schedule faropenem medoxomil under HS 29419000 and SITC 54139.

As of Q4 2014, FAROPENEM MEDOXOMIL remains US FDA's Preferred Term for this commodity. Faropenem medoxomil bears US NLM identifiers UMLS ID C1880735 and NCI Concept Code C65621. SMILES: CC1C(OC(=O)O1)COC(=O)C2=C(S[C@H]3N2C(=O)[C@@H]3[C@@H](C)O)[C@H]4CCCO4.

UNSPSC 51282129 Faropenem medoxomil is a Commodity code, but the recent state and local opportunities posted under it show no alignment with this specific antibiotic product. Instead, the code is being used to solicit naloxone and drug deactivation systems, pharmaceutical generic multi-source products and OTC supplies, medical and first aid supplies for emergency responders, and direct-to-manufacturer prescription program capabilities—none of which are faropenem medoxomil or related beta-lactam antimicrobials. The mismatch between the code's nominal scope and actual procurement activity suggests that either the code is being misapplied by issuing bodies or the recent opportunities have been incorrectly tagged. State and local governments are clearly buying emergency pharmaceutical supplies, first aid materials, and generic pharmaceuticals through these solicitations, but not the specific drug product the code nominally covers.

The issuing bodies span county health departments (Seminole County, Florida), municipal fire departments (Tampa Fire Department via the City of Tampa), state health and human services agencies (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota MMCAP serving multiple state and local jurisdictions including Oregon). Recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), the City of Tampa's IFB for medical and first aid supplies estimated at $700,000 (due March 13, 2026, with a five percent SLBE bid discount), Texas HHS's RFI for direct-to-manufacturer prescription programs (response deadline April 3, 2026), and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products (due March 26, 2026). Activity is concentrated in Florida, Texas, and Minnesota, with cooperative purchasing extending across multiple western and Midwestern states. The absence of recent opportunities specifically for faropenem medoxomil indicates that this code does not reflect current state and local purchasing patterns and may not be a viable pursuit avenue unless the tagging error is corrected at source.